Regenexx Rotator Cuff Stem Cell Procedure Study

Shoulder Rotator Cuff Study Patient Requirements

  • The patient must be willing to come to the Broomfield clinic for first an initial evaluation to make a final determination of study eligibility (includes diagnostic ultrasound)
  • There is no guarantee they will be eligible
  • The cost of this evaluation will be billed to the patient and/or their insurance
  • If eligible, the patient must be willing to return for treatment at the Broomfield clinic and for all post-injection treatments (6 weeks, 3 months, 6 months, 12 months, 24 months)
  • Costs of any travel will be the responsibility of the patient
  • The patient will be randomized to receive either Regenexx-SD treatment or be instructed in a home exercise therapy program
  • Patients in the exercise therapy group will have the opportunity to receive a Regenexx SD treatment after the three month visit if they do not respond to the exercise therapy
  • The Regenexx SD treatment will be provided at no cost to the patient
  • The patient must have a shoulder MRI current within the last year at their own cost for study screening purposes.
  • The subject must meet all inclusion criteria and not meet any exclusion criteria (complete list below). Key criteria include:
    • Age 18-65
    • Can comply with all post-operative evaluations and visits
    • No previous surgery to the affected shoulder
    • No current or past malignancy (cancer)

Inclusion Criteria

Candidates must meet ALL of the following:

  • Voluntary signature of the IRB approved Informed Consent,
  • Skeletally mature Male or Female ages 18 to 65
  • Unremitting pain in the affected shoulder having failed conservative treatment (e.g. NSAIDs, physician initiated physical therapy or a corticosteroid injection) for at least 3 months
  • Significant functional disability related to pain, lack of strength, or other shoulder symptoms
  • Physical examination consistent with Rotator Cuff tea
  • Positive diagnostic imaging, which may include arthrogram, ultrasound and/or MR, on the affected shoulder indicating a non-retracted supraspinatus tendon tear comprising at least one half the tendon thickness in the anterior-posterior and/or superior-inferior planes
  • Reasonable movement of the non-treated arm, defined as a shoulder elevation of equal or more than 90°, and able to perform (post-injection) exercises
  • Is independent, ambulatory, and can comply with all post-operative evaluations and visits

Exclusion Criteria

Candidates will be excluded if they meet ANY of the following:

  • A massive rotator cuff tear as demonstrated by Grade 3 or less muscle strength on testing internal and external rotation of the affected shoulder
  • Previous surgery to the affected shoulder
  • Prior rotator cuff prolotherapy, PRP or other RC injection-based therapies within the past three months,
  • Concomitant tears of multiple rotator cuff or biceps tendons
  • Grade 2 or greater SLAP tear
  • Type 3 acromion
  • Significant bone spur in subacromial space
  • Inflammatory or auto-immune based joint diseases or other upper extremity pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout)
  • Quinolone or Statin induced myopathy/ tendinopathy
  • Kellgren-Lawrence grade 2 or greater glenohumeral osteoarthritis
  • Adhesive capsulitis (mild or severe)
  • Symptomatic cervical spine pathology (e.g. radicular cervical pain)
  • Severe neurogenic inflammation of the cutaneous nerves about the shoulder
  • Shoulder instability requiring surgical stabilization
  • Contraindications for MRI
  • Tested positive or has been treated for a malignancy in the past or is suspected of having a malignancy or is currently undergoing radiation or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed injection site
  • Condition represents a worker’s compensation case
  • Currently involved in a health-related litigation procedure
  • Is pregnant
  • Bleeding disorders
  • Currently taking anticoagulant or immunosuppressive medication
  • Allergy or intolerance to study medication
  • Use of chronic opioid,
  • Documented history of drug abuse within six months of treatment
  • Any other condition, that in the opinion of the investigator, that would preclude the patient from enrollment

If you meet all of the criteria for a study and are able to travel to the research study location for all of the required follow-up of visits, please contact us at 303.495.4014.